In conclusion, from in vitro experiments to in vivo experiments, from cell level to animal level and then to human tissue sample level, this study proved the positive regulation of BPTF on VEGF in NSCLC, and the high expression of BPTF may predict the better efficacy of bevacizumab treatment. Therefore, it provides an important theoretical and experimental basis for developing BPTF/VEGF signaling axis as a candidate therapeutic target and potential prognostic marker of NSCLC. This evidence concerns the gene BPTF and non-small cell lung carcinoma.